Rigel Pharmaceuticals, Inc.
RIGL
$18.47
-$0.14-0.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 37.18M | 17.49M | 3.88M | -14.23M | -19.80M |
| Total Depreciation and Amortization | 2.43M | 2.23M | 1.92M | 1.60M | 1.28M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.81M | 11.61M | 11.41M | 10.68M | 10.49M |
| Change in Net Operating Assets | -13.83M | 153.00K | -6.48M | -10.35M | 1.35M |
| Cash from Operations | 35.59M | 31.47M | 10.73M | -12.31M | -6.68M |
| Capital Expenditure | -36.00K | -36.00K | -10.00K | -- | -- |
| Sale of Property, Plant, and Equipment | 98.00K | 98.00K | 136.00K | 132.00K | 132.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6.80M | 4.07M | 8.04M | 3.07M | -4.89M |
| Cash from Investing | -6.74M | 4.13M | 8.17M | 3.20M | -4.76M |
| Total Debt Issued | -- | -- | 0.00 | 0.00 | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.36M | 1.96M | 985.00K | 836.00K | 1.14M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -11.00M | -13.61M | -13.61M | -4.48M | -4.41M |
| Cash from Financing | -8.65M | -11.64M | -12.62M | -3.65M | -3.27M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 20.21M | 23.96M | 6.28M | -12.76M | -14.71M |